Why not to use colchicine in COVID-19? An oldanti-inflammatory drug for a novel auto-inflammatory disease

Affiliations

¹ Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili and University of Brescia, Brescia.
² Hospital Infection Committee (CIO).
³ Internal Medicine Unit, ASST Valcamonica, Esine (Brescia), Italy.

Comment

Silvia Piantoni et al. Rheumatology (Oxford). 2020.

. 2020 Jul 1;59(7):1769-1770.

doi: 10.1093/rheumatology/keaa217.

¹ Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili and University of Brescia, Brescia.
² Hospital Infection Committee (CIO).
³ Internal Medicine Unit, ASST Valcamonica, Esine (Brescia), Italy.

No abstract available

Comment on

COVID-19: an unexpected indication for anti-rheumatic therapies?
Lucchino B, Di Franco M, Conti F. Lucchino B, et al. Rheumatology (Oxford). 2020 Jun 1;59(6):1200-1203. doi: 10.1093/rheumatology/keaa194. Rheumatology (Oxford). 2020. PMID: 32374874 Free PMC article. No abstract available.

1. Mehta P, McAuley DF, Brown M. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033–4. - PMC - PubMed
1. Lucchino B, Di Franco M, Conti F.. COVID19: An unexpected indication for anti-rheumatic therapies? Rheumatol 2020. - PMC - PubMed
1. Leung YY, Hui LLY, Kraus VB.. Colchicine-update on mechanism of action and therapeutic uses. Semin Arthritis Rheum 2015;45:341–50. - PMC - PubMed
1. Milewska A, Nowak P, Owczarek K. et al. Entry of human coronavirus NL63 into the cell. J Virol 2018;92:e01933–17. - PMC - PubMed
1. Gultekin N, Kucukates E.. Microtubule inhibition therapy by colchicine in severe myocarditis especially caused by Epstein-Barr and cytomegalovirus co-infection during a two-year period: a novel therapeutic approach. J Pak Med Assoc 2014;64:1420–3. - PubMed